Camrelizumab plus CAPOX versus CAPOX for HER2-negative gastric or gastro-oesophageal junction adenocarcinoma: a cost-effectiveness analysis
ObjectiveThis study was to assess the cost-effectiveness of camrelizumab in combination with capecitabine plus oxaliplatin (CAPOX) compared to CAPOX for human epidermal growth factor receptor 2 (HER2)-negative advanced gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC) in China.MethodsA...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Frontiers Media S.A.
2026-07-01
|
| Серія: | Frontiers in Pharmacology |
| Предмети: | |
| Онлайн доступ: | https://www.frontiersin.org/articles/10.3389/fphar.2026.1854496/full |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|